B. Riley Securities Maintains Buy on Arrowhead Pharma, Raises Price Target to $123
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsPrice Target
B. Riley Securities analyst Madison El-Saadi maintains Arrowhead Pharma (NASDAQ:ARWR) with a Buy and raises the price target from $101 to $123.
B. Riley Securities analyst Madison El-Saadi maintains Arrowhead Pharma (NASDAQ:ARWR) with a Buy and raises the price target from $101 to $123.